Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

Trep-AB

financed

Closed

Repurposing clinically approved antibacterial drugs for treponematoses therapy

Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because th... see more

31/01/2025

FUNDACION PRIVADA...

1M€

Project Budget: 1M€

Project leader

FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 100K€

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 4 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2025-01-31

ERC-2019-STG: ERC Starting Grant Scope:Objectives

I+D

Cerrada does 6 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

FUNDACION PRIVADA DE LUCHA C...

1.15M€ | Leader

PROYECTO FONTANELLAS Y MARTI

853.47K€ | participant

UNIVERSITY OF WASHINGTON

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 60 months Date Start: 2020-01-29
End date: 2025-01-31

Project leader

FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 100K€

Project Budget 1M€

participation deadline Sin fecha límite de participación.

Project description Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a research program to have other validated treatment options with good CNS penetration that are efficacious for all the stages of treponemal infection. Our preliminary results using computational prediction of drug activity based on similarity to drugs with known activity against T.p. and other spirochetes shows several candidate antibiotics. I will take advantage of recent developments in culture methods for determination of drug susceptibility to test 20 prioritized drugs. These results will be confirmed in experimentally infected rabbits treated with the investigational drugs and assessed for lesion development and T.p. burden. My second approach will exploit the established expertise of my team conducting randomized clinical trials to evaluate the efficacy of the 2 most promising candidates compared to standard treatment to cure patients with syphilis/yaws. Such studies will incorporate in-depth studies of recurrent events among study participants, to further clarify the biological basis and identify mutations that confer resistance to B-lactams. New antibacterial oral drugs for the treatment of treponematoses will be a tremendous resource in case of penicillin treatment-failure, resistance, shortage, allergy, or for use in yaws combination regimens to reduce the likelihood of resistance selection.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers